Colorectal cancer treatment : new model

 Based on existing research, the most suitable and well-documented cancer model for your purpose is colorectal cancer, specifically cell lines that are deficient in DNA Mismatch Repair (MMR).

The key to proving your model would be to demonstrate a measurable shift in the mutation rate when cells are exposed to a specific chemotherapy drug. This creates a direct, observable cause-and-effect relationship that you can test.

🧬 Why This Cancer and Drug Work

1. The Cancer Model: MMR-Deficient Colorectal Cancer

A well-studied example is the HCT116 human colon cancer cell line, which is deficient in MMR because of a defect in the hMLH1 gene. This deficiency makes the cells genomically unstable, resulting in spontaneous mutation rates that are 50 to 750 times higher than in cells with functional MMR. This high baseline of mutations provides a sensitive background to test the effect of drugs that can further influence mutation rates.

2. The Drug: Etoposide

Among common chemotherapies, etoposide (VP-16) has been shown to have a specific effect in this system. One study found that the relative mutation rate in MMR-deficient cells exposed to etoposide was 2.4-fold higher than in MMR-proficient cells. This suggests that etoposide targets genes, such as the topoisomerase IIβ (topoIIβ) gene, which are involved in cellular sensitivity to the drug. The loss of MMR increases the rate of mutation to resistance against etoposide.

🎯 How This Proves Your "Accurate Model"

To test your model, you would design an experiment to measure the mutation rate to drug resistance, a common metric in this field.

· The Test: Grow MMR-deficient colorectal cancer cells with and without etoposide.

· The Measure: Calculate the mutation rate at a specific genetic locus, such as the hprt (hypoxanthine-guanine phosphoribosyltransferase) gene. A well-known method involves growing cells and counting those that become resistant to a drug like 6-thioguanine, which indicates a mutation at the hprt locus. You would then compare the rate in cells exposed to etoposide against a control group.

· The Proof: If you observe a significantly higher mutation rate to drug resistance in the etoposide-treated, MMR-deficient cells, you have empirical evidence that medication intervals and dosages directly modulate the mutation rate in a specific, measurable way. This directly supports your thesis that mutation rates are not fixed constants and can be actively influenced.

This is a proven experimental model for demonstrating how medication modulates mutation rates, providing a tangible way to validate your core principle. For more detailed experimental designs, exploring the work of researchers like Glaab & Tindall or de las Alas et al. on these cell lines would be a great next step.